Trinity Biotech OK’d to launch PreClara test

Trinity Biotech plc filed a report noting that it has received regulatory approval to begin offering its FDA-cleared PreClara™ preeclampsia testing service.

Rhea-AI Filing Summary

Trinity Biotech plc filed a report noting that it has received regulatory approval to begin offering its FDA-cleared PreClara™ preeclampsia testing service. This approval allows the company to start providing a diagnostic testing service aimed at detecting preeclampsia, a serious pregnancy-related condition. The company communicated this development through a press release dated August 14, 2025, which is attached as an exhibit to the report.

Insights

Healthcare diagnostics analyst

Regulatory approval lets Trinity Biotech launch its PreClara preeclampsia test service.

Trinity Biotech reports that it has received regulatory approval to begin its FDA-cleared PreClara™ preeclampsia testing service. This means the company can move from development into actual service delivery for this diagnostic, which targets preeclampsia, a significant complication in pregnancy.

The mention of FDA clearance indicates that the underlying test has already passed a defined U.S. regulatory review, and the new approval pertains to starting the testing service itself. While no volumes or revenue figures are provided, gaining permission to offer such a service can broaden the company’s test menu and potentially support future growth once adoption levels become clearer.

The report ties this update to a press release dated August 14, 2025, suggesting the service launch is aligned with that communication. Future company filings may provide details on uptake of the PreClara service, such as testing volumes or any impact on overall diagnostics revenue.

FAQ

What key update does Trinity Biotech (TRIB) report in this filing?

The company reports that it has received regulatory approval to begin offering its FDA-cleared PreClara™ preeclampsia testing service, and it has issued a related press release.

What is the PreClara™ preeclampsia testing service from Trinity Biotech (TRIB)?

PreClara™ is described as an FDA-cleared preeclampsia testing service aimed at detecting preeclampsia, a serious pregnancy-related condition, which Trinity Biotech is now approved to begin offering.

When did Trinity Biotech receive approval to begin the PreClara testing service?

Trinity Biotech states that on August 14, 2025, it issued a press release announcing that it had received regulatory approval to begin its FDA-cleared PreClara™ preeclampsia testing service.

Is the PreClara preeclampsia test FDA-cleared according to Trinity Biotech?

Yes. The filing specifies that Trinity Biotech’s PreClara™ preeclampsia testing service is FDA-cleared, and that the company has received regulatory approval to begin providing this service.

Where can investors find more detail about Trinity Biotech’s PreClara approval?

The report states that a press release titled “Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service” is attached as Exhibit 99.1.

Does this Trinity Biotech filing include financial results or earnings data?

No. This filing focuses on the regulatory approval and start of the PreClara™ testing service and does not present financial or earnings data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/15/2025 - 10:24 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

F O R M 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

TRINITY BIOTECH PLC

(Name of Registrant)

IDA Business Park

Bray, Co. Wicklow, Ireland

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070).

EXPLANATORY NOTE

On August 14, 2025, the Company issued a press release announcing it had received regulatory approval to begin FDA-Cleared PreClara™ preeclampsia testing service. A copy of the press release is filed herewith as Exhibit 99.1.

EXHIBIT INDEX

Exhibit		Description
99.1		Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TRINITY BIOTECH PLC
		Trinity Biotech plc
		(Registrant)
	By:	/s/ John Gillard
		John Gillard
		Chief Executive Officer

Date: August 14, 2025